Daré Bioscience Reports First Quarter 2019 Financial Results and Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Dare Bioscience (DARE) Tops Q1 EPS by 3c
May 14, 2019 4:01 PM EDTDare Bioscience (NASDAQ: DARE) reported Q1 EPS of ($0.27), $0.03 better than the analyst estimate of ($0.30).
The first quarter was an active one for Daré and positioned us well for the year ahead, said Sabrina Martucci Johnson, President and CEO of Daré. We believe our differentiated product... More
